In the current study we describe the enhanced anti-tumor activity of the dual PI3K/mTOR inhibitor PF-502 and the MEK inhibitor PD-901 in in vitro and in vivo models of colorectal cancer. The gene discussed is MAP2K7; the disease is neoplasm.